MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jcin.2025.07.014

Медицинская библиотека · JACC. Cardiovascular interventions · 2025

CLASP IID Trial and Registry: 2-Year Outcomes of Transcatheter Repair for Degenerative Mitral Regurgitation.

Makkar Raj, Zahr Firas, Chakravarty Tarun, Chadderdon Scott, Makar Moody, Ruf Tobias Friedrich, Kipperman Robert M, Rassi Andrew N, Hausleiter Jörg, Smith Robert L, Szerlip Molly, Goldman Scott, Lim D Scott, Inglessis-Azuaje Ignacio, Yadav Pradeep, Lurz Philipp, Kister Tobias, Davidson Charles J, Mumtaz Mubashir, Gada Hemal, Kar Saibal, Kodali Susheel K, Laham Roger, Hiesinger William, Fam Neil P, Keßler Mirjam, O'Neill William W, Whisenant Brian, Kliger Chad, Rudolph Volker, Hermiller James, Dhoble Abhijeet, Smalling Richard, Latib Azeem, Lazkani Mohamad, Choo Joseph, Garcia Santiago, Rodés-Cabau Josep, Schofer Niklas, Baldus Stephan, Kapadia Samir, Koulogiannis Konstantinos, Marcoff Leo, Gillam Linda D, von Bardeleben Ralph Stephan, CLASP IID Trial and Registry Investigators

СтатьяРандомизированное исследованиеМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

One-year outcomes from the CLASP IID Trial (Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial; NCT03706833) and Registry established the PASCAL transcatheter valve repair system as a safe and effective treatment for prohibitive-risk degenerative mitral regurgitation (DMR). Longer-term follow-up is ongoing.

OBJECTIVES

This paper reports the CLASP IID Trial and Registry 2-year outcomes.

METHODS

In the CLASP IID Trial, prohibitive-risk patients with 3+/4+ DMR, deemed suitable for both the PASCAL and MitraClip systems, were randomized 2:1 (PASCAL: n = 204; MitraClip: n = 96). Patients with complex anatomy deemed ineligible for randomization were enrolled in the CLASP IID Registry (N = 98) and treated with the PASCAL system.

RESULTS

In the randomized cohort, significant and sustained MR reduction was achieved at 2 years. MR ≤2+ rate was 95.0% (96/101) in the PASCAL group vs 91.5% (54/59) in the MitraClip group (P = 0.500), and MR ≤1+ rate was 77.2% (78/101) vs 67.8% (40/59) (P = 0.198), respectively. Kaplan-Meier estimates for freedom from all-cause mortality, cardiovascular mortality, heart failure hospitalization, and nonelective mitral valve reinterventions were 80.8% vs 86.2% (P = 0.216), 88.6% vs 90.4% (P = 0.666), 86.4% vs 94.3% (P = 0.058), and 97.9% vs 97.9% (P = 0.962), respectively. In the registry cohort, 91.9% (34/37) achieved MR ≤2+ and 64.9% (24/37) achieved MR ≤1+. Kaplan-Meier estimates for freedom from all-cause mortality, cardiovascular mortality, heart failure hospitalization, and nonelective mitral valve reinterventions were 77.2%, 84.0%, 85.1%, and 99.0%, respectively. Significant improvements in functional status and quality of life were observed in both cohorts.

CONCLUSIONS

Two-year outcomes from the CLASP IID Trial and Registry show favorable survival, and significant and sustained MR reduction with functional and quality-of-life improvements, confirming sustained safety and effectiveness of the PASCAL system in treating a broad population of DMR patients.

Для цитирования: Makkar Raj, Zahr Firas, Chakravarty Tarun, Chadderdon Scott, Makar Moody, Ruf Tobias Friedrich, Kipperman Robert M, Rassi Andrew N, Hausleiter Jörg, Smith Robert L, Szerlip Molly, Goldman Scott, Lim D Scott, Inglessis-Azuaje Ignacio, Yadav Pradeep, Lurz Philipp, Kister Tobias, Davidson Charles J, Mumtaz Mubashir, Gada Hemal, Kar Saibal, Kodali Susheel K, Laham Roger, Hiesinger William, Fam Neil P, Keßler Mirjam, O'Neill William W, Whisenant Brian, Kliger Chad, Rudolph Volker, Hermiller James, Dhoble Abhijeet, Smalling Richard, Latib Azeem, Lazkani Mohamad, Choo Joseph, Garcia Santiago, Rodés-Cabau Josep, Schofer Niklas, Baldus Stephan, Kapadia Samir, Koulogiannis Konstantinos, Marcoff Leo, Gillam Linda D, von Bardeleben Ralph Stephan, CLASP IID Trial and Registry Investigators. CLASP IID Trial and Registry: 2-Year Outcomes of Transcatheter Repair for Degenerative Mitral Regurgitation.. JACC. Cardiovascular interventions. 2025. DOI: 10.1016/j.jcin.2025.07.014.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.